Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

4imprint H1 operating profits edge higher despite modest revenue decline

(Sharecast News) - Promotional products specialist 4imprint said on Wednesday that operating profits had edged higher in H1, even as revenues ticked lower, as it was forced to navigate a challenging customer acquisition landscape. 4imprint said revenues for the six months ended 28 June fell 1% year-on-year to $659.4m, but operating profit edged up 1% to $70.7m, supported by an improved margin of 10.7%, up from 10.5% a year earlier. Pre-tax profits also rose 1%, coming to $74.0m in the half, reflecting disciplined cost control and pricing adjustments.

The FTSE 250-listed firm noted that customer metrics were mixed in H1, with total orders declining to 1.05m from 1.09m, and new customer acquisitions falling 13.8% to 125,000. However, it noted that retention remained robust and average order values held firm.

Free cash flow jumped 26.2% to $74.6m, though cash reserves fell 16% to $102.3m following the payout of $119.9m in final and special dividends. 4imprint also maintained its interim dividend of USD 80 cents per share.

Chairman Paul Moody said: "Despite some market challenges and an anticipated level of rising product cost due to tariffs in the second half, the board expects that full year group revenue and profit before tax will remain within the current range of analysts' forecasts.

"The board is confident in the group's ability to navigate current market conditions, delivering the strongest possible near-term financial results while positioning the business to take advantage of opportunities that will present themselves as conditions improve."

As of 0855 BST, 4imprint shares were down 4.40% at 3,455.86p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.